Clinical Trials

More research is needed to better understand DCIS. This includes laboratory research, where scientists study patient tissue samples to learn more about the biology of DCIS, and clinical trial research.
What is a Clinical Trial?
A clinical trial is a research study involving patients that strives to answer a specific medical question. It is the critical step when scientific inquiry and testing moves from a lab to “real world” human subjects. Clinical trials are essential to the advancement of scientific and medical knowledge. The data obtained from clinical trials leads to improvements in how we prevent, diagnose and treat disease.
Should I Participate in a Clinical Trial?
There are many different types of clinical trials. Each trial has different eligibility requirements and not every patient qualifies for every trial.
There are benefits and risks to participating in any trial. As a trial participant, you may have access to new treatments that are not available to the general public, you will be closely monitored by your medical team, and you may feel good knowing that your participation will help future patients. There can also be downsides to participating, the main one being potential side effects from a new treatment. Depending on the location and type of trial, you may need to travel a far distance to participate, which can cost time and money.
There are many safety protections in place for clinical trial participants. The health and well-being of participants are closely monitored and there are ongoing safety reviews by independent committees. If at any time a trial is determined to be unsafe to participants, it is stopped. Patients are also free to withdraw at any time.
Participating in a clinical trial is a very personal decision and one that you should make in consultation with your doctor and family.
How Do I Find Out About Clinical Trials?
You can ask your doctor if you are eligible for any clinical trials. Keep in mind that not every doctor knows about every clinical trial. If you are receiving care at a research hospital, your doctor is more likely to know about clinical trials.
You can also do your own research about clinical trial options. We recommend the following search tools:
- BreastCancerTrials.org is a clinical trial matching service that helps people with any stage of breast cancer learn about and find clinical trials that are right for them. It lists over 500 clinical trials that are actively recruiting patients in the United States.
- ClinicalTrials.gov is the U.S. government’s database of clinical trials. It includes clinical trials from around the world.
Both of these databases include tools to search by location and medical condition. You can see trials specifically for DCIS by entering “DCIS” or “ductal carcinoma in situ” in the search box.
If you find a clinical trial on the Internet and think you might want to enroll, speak to your doctor about it.
Clinical Trials for DCIS
Clinical trials involving DCIS patients often compare a new treatment to the standard of care. The results can inform how to refine standard of care and provide more options for future DCIS patients.
Currently, there is a very exciting clinical trial underway in the U.S. that could potentially change the standard of care for treating low risk DCIS. Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) trial is studying whether active monitoring (with or without hormone therapy) is a safe alternative to surgery for low-risk DCIS patients. Similar studies are also taking place in Europe. While COMET is no longer recruiting patients, other active monitoring trials currently recruiting patients include the RECAST trial in the United States and the LORD trial in the Netherlands.
At any given time, there are hundreds of clinical trials taking place across the U.S. and internationally involving DCIS patients. Below is our own complication based on our own search of ClinicalTrials.gov. To use this database, you can sort by clicking on the column headings or you can enter location or keyword terms into the search box. (If you are based in the United States, enter your state. If you are based outside the U.S., enter your country).
We try to keep this database current but due to the ever-changing nature of studies, it is neither exhaustive nor error-free. We strongly recommend confirming any information you find below with ClinicalTrials.gov and BreastCancerTrials.org for the most up-to-date information.
Please note that we are in the process of re-designing and populating the database below and appreciate your patience while we do so.
Start Year | Name | Study URL | Status | Locations | Keywords |
---|---|---|---|---|---|
2018 | MRI in Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT03543397 | Unknown | Strasbourg, France | |
2009 | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | https://clinicaltrials.gov/study/NCT00857714 | Terminated | Indiana | Lapatinib |
2024 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | https://clinicaltrials.gov/study/NCT06075953 | Recruiting | Berkeley, San Francisco, California; Winston-Salem, North Carolina; Bryn Mawr, Media, Paoli, Wynnewood, Pennsylvania; Nashville, Tennessee | Tamoxifen; Exemestane; Letrozole; Anastrazole; Testosterone; Elacestrant; Z-endoxifen |
1995 | Wide Excision Alone As Treatment for Ductal Carcinoma in Situ of the Breast | https://clinicaltrials.gov/study/NCT00165256 | Active Not Recruiting | Boston, Massachusetts | Observation |
2025 | Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) | https://clinicaltrials.gov/study/NCT06868238 | Not Yet Recruiting | Magtrace | |
2017 | Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT02908178 | Completed | Bethesda, Maryland | Sentinel lymph node biopsy (SLNB) |
2016 | Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT02872025 | Active Not Recruiting | San Francisco, California | Pembrolizumab; Intralesional mRNA |
2008 | Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) | https://clinicaltrials.gov/study/NCT00669747 | Unknown | Oklahoma City, Oklahoma; Houston, Texas | Carboplatin; Normal Saline |
2010 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT01060345 | Terminated | Chicago, Illinois | Polyphenon |
2017 | Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS | https://clinicaltrials.gov/study/NCT02926911 | Active Not Recruiting | Anchorage, Alaska; Phoenix, Arizona; Duarte, Los Angeles, San Diego, Vallejo, California; Denver, Lafayette, Colorado; New Haven, Connecticut; Washington, District of Columbia; Hollywood, Jacksonville, Florida; Honolulu, Hawaii; Post Falls, Idaho; Chicago, Evanston, Harvey, Peoria, Rockford, Urbana, Illinois; Des Moines, Iowa City, Iowa; Kansas City, Kansas; Edgewood, Lexington, Kentucky; Baton Rouge, New Orleans, Louisiana; Brewer, Scarborough, Maine; Annapolis, Baltimore, Maryland; Boston, Massachusetts; Ann Arbor, Detroit, Grand Rapids, Royal Oak, Michigan; Minneapolis, Rochester, Saint Louis Park, Minnesota; Saint Louis, Missouri; Anaconda, Billings, Bozeman, Great Falls, Kalispell, Missoula, Montana; Omaha, Nebraska; Hooksett, New Hampshire; Englewood, Hackensack, Morristown, Neptune, Paramus, New Jersey; Albuquerque, New Mexico; Bronx, Buffalo, New York, Syracuse, New York; Chapel Hill, Charlotte, Durham, Fayetteville, Goldsboro, Greensboro, Greenville, New Bern, Raleigh, Winston-Salem, North Carolina; Belpre, Centerville, Columbus, Dayton, Delaware, Findlay, Franklin, Greenville, Kettering, Mansfield, Marietta, Marion, Newark, Westerville, Youngstown, Zanesville, Ohio; Lawton, Oklahoma; Bend, Oregon; Pittsburgh, Sayre, York, Pennsylvania; Providence, Rhode Island; Charleston, Georgetown, Greenville, South Carolina; Memphis, Tennessee; Dallas, Houston, Laredo, Texas; Salt Lake City, Utah; Burlington, Vermont; Morgantown, Norfolk, Richmond, Virginia; Bellevue, Washington; Appleton, Burlington, Fond Du Lac, Germantown, Grafton, Green Bay, Kenosha, Madison, Marinette, Milwaukee, Oshkosh, Racine, Sheboygan, Summit, Two Rivers, Wauwatosa, West Allis, Wisconsin | Active monitoring; Active surveillance |
2021 | Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT05218044 | Recruiting | Glendale, California | Cryoablation; Tumor Freezing |
2003 | MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ | https://clinicaltrials.gov/study/NCT00586326 | Completed | Phoenix, Arizona; Inglewood, Los Angeles, California; Miami Beach, Florida; Baltimore, Maryland; Royal Oak, Michigan; New York, New York; Philadelphia, Pennsylvania; Providence, Rhode Island; Houston, Texas; Richmond, Virginia; Seattle, Washington | MammoSite Radiation Therapy System |
2005 | Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast | https://clinicaltrials.gov/study/NCT00496808 | Completed | Houston, Texas | Herceptin; Trastuzumab |
2016 | Evaluation of the DCIS Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS | https://clinicaltrials.gov/study/NCT02766881 | Completed | Canada, various location | |
2024 | Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer | https://clinicaltrials.gov/study/NCT06540872 | Not Yet Recruiting | Germany, various locations | [68Ga]Ga-FAPI-46 |
2021 | Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT03775213 | Completed | Durham, North Carolina | Decision Support Tool; Active Monitoring; Active Surveillance |
2017 | Intraoperative Radiation Therapy (IORT) in DCIS | https://clinicaltrials.gov/study/NCT03216421 | Active Not Recruiting | New York, New York | Quality of Life Questionnaires |
2018 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery | https://clinicaltrials.gov/study/NCT03535506 | Terminated | Washington, District of Columbia | Palbociclib |
2019 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT04144023 | Recruiting | Jacksonville, Florida; Rochester, Minnesota | Granulocyte-Macrophage Colony-Stimulating Factor; Multi-epitope HER2 Peptide Vaccine H2NVAC; Echocardiography; Biospecimen Collection; Biopsy |
2015 | MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | https://clinicaltrials.gov/study/NCT02352883 | Active Not Recruiting | San Diego, San Marcos, California; Greenwich, Hartford, Meriden, New Britain, Connecticut; Newark, Delaware; Atlantis, Florida; Chicago, Harvey, Naperville, Plainfield, Springfield, Illinois; Avon, Indianapolis, Mishawaka, South Bend, Indiana; Dodge City, El Dorado, Lawrence, Salina, Wellington, Wichita, Winfield, Kansas; Owensboro, Kentucky; Baton Rouge, New Orleans, Louisiana; Salisbury, Maryland; Minneapolis, Minnesota; Saint Louis, Springfield, Missouri; Flemington, Mount Holly, Somerville, Voorhees, New Jersey; Bronx, New York; Asheville, Winston-Salem, North Carolina; Canton, Cincinnati, Ohio; Bryn Mawr, Easton, Gettysburg, Hershey, Media, Paoli, Philadelphia, Phoenixville, Pottstown, Wynnewood, York, Pennsylvania; Providence, Rhode Island; Spartanburg, South Carolina; Dallas, Texas; Salt Lake City, Utah; Seattle, Washington; Oconomowoc, Waukesha, Wausau, Wisconsin | MRI; Radiation; Endocrine Therapy; Quality-of-Life Assessment; Biomarker; Cytology |
2009 | Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) | https://clinicaltrials.gov/study/NCT01023477 | Completed | Fairfax, Falls Church, Virginia | Chloroquine; Biopsy |
2022 | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT04797299 | Recruiting | Canada, various locations | |
2008 | Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast | https://clinicaltrials.gov/study/NCT01841749 | Completed | Bordeaux, Aquitaine, France | Sentinel node biopsy; Mastectomy |
2007 | Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast | https://clinicaltrials.gov/study/NCT00470236 | Unknown | Various location in Australia (including locations in New South Wales, Queensland, South Australia and Tasmania; Belgium; Canada; France; Ireland; Italy; Netherlands; New Zealand; Singapore; Switzerland; United Kingdom | Radiation; Fractionation |
2004 | Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women | https://clinicaltrials.gov/study/NCT00256217 | Completed | Orange, California | Anastrozole |
2016 | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT02636582 | Completed | Boston, Massachusetts; New York, New York; Philadelphia, Pennsylvania; Houston, Texas | Biomarker; Nelipepimut-S Plus GM-CSF Vaccine; Sargramostim |
2025 | The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS | https://clinicaltrials.gov/study/NCT06217458 | Not Yet Recruiting | Croatia | Contrast Enhanced Mammography |
2006 | Breast MRI as a Preoperative Tool for DCIS | https://clinicaltrials.gov/study/NCT00605982 | Active Not Recruiting | Basking Ridge, New Jersey; Commack, New York, New York | MRI |
2015 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | https://clinicaltrials.gov/study/NCT02127073 | Terminated | New York, New York | Intranasal Oxytocin |
2019 | Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast | https://clinicaltrials.gov/study/NCT03878342 | Active Not Recruiting | France, various locations | Radiation; Radiotherapy |
2023 | Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS | https://clinicaltrials.gov/study/NCT05912569 | Recruiting | Seoul, Korea | Delay sentinel node biopsy |
2009 | DC Vaccine for Patients With Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT02061332 | Completed | Philadelphia, Pennsylvania | HER-2 Pulsed Dendritic cell Vaccine |
2017 | Management of Low-risk (Grade I and II) DCIS | https://clinicaltrials.gov/study/NCT02492607 | Recruiting | Netherlands, various locations | Digital Mammography; Radiation; Radiotherapy |
2016 | Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS) | https://clinicaltrials.gov/study/NCT03148015 | Completed | Newport News, Virginia | Biomarkers |
2017 | The PROMISE Study: Duavee in Women With DCIS | https://clinicaltrials.gov/study/NCT02694809 | Completed | Aurora, Colorado; Chicago, Geneva, Lake Forest, Illinois; Baltimore, Maryland; Boston, Massachusetts; Saint Louis, Missouri; Philadelphia, Pittsburgh, Pennsylvania; Salt Lake City, Utah | Conjugated Estrogens/Bazedoxifene; Biomarker; Placebo; Quality-of-Life Assessment; Questionnaire Administration |
2017 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | https://clinicaltrials.gov/study/NCT02993159 | Completed | Chicago, Illinois; Edgewood, Kentucky; Rochester, Minnesota; New York, New York; Durham, North Carolina; Cleveland, Ohio | Afimoxifene; Biomarker; Placebo; Tamoxifen Citrate |
2024 | Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT06218303 | Recruiting | Pittsburgh, Pennsylvania | MUC1 Peptide Vaccine; Hiltonol®; Aromatase Inhibitor |
2010 | Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates | https://clinicaltrials.gov/study/NCT05961280 | Completed | Mastectomy; Sentinel lymph node biopsy | |
2020 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ | https://clinicaltrials.gov/study/NCT04722692 | Recruiting | Houston, Texas; Hong Kong; Sweden, various locations | |
2012 | A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT01628536 | Completed | New Haven, Connecticut | Black cohosh |
2013 | Impact of Radiation Therapy on Breast Conservation in DCIS | https://clinicaltrials.gov/study/NCT02248662 | Completed | Boston, Massachusetts; Hanover, New Hampshire; Madison, Wisconsin | |
2006 | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT00183963 | Terminated | Los Angeles, California | Tamoxifen; Fulvestrant |
2008 | Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT00804128 | Completed | San Francisco, California | Magnetic Resonance Imaging; MRI; Gadavist |
2019 | Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT04046159 | Recruiting | Taipei, Taiwan | Low-dose Tamoxifen; Radiation; Radiotherapy |
2020 | Subzero and Scorpion Trial | https://clinicaltrials.gov/study/NCT05032079 | Withdrawn | Miami, Florida | Cryoablation |
2019 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | https://clinicaltrials.gov/study/NCT02856503 | Withdrawn | Vitamin D3 | |
2008 | Intraoperative Gamma Camera for Breast Cancer Surgery | https://clinicaltrials.gov/study/NCT00757302 | Completed | Strasbourg, France | SLN procedure (CarolIReS camera) |
2019 | Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS | https://clinicaltrials.gov/study/NCT03703492 | Completed | Madison, Wisconsin | (18F)FES|DRGadobenate dimeglumine |
2009 | Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ | https://clinicaltrials.gov/study/NCT00555152 | Completed | Birmingham, Alabama; Houston, Texas | Biomarker; Lapatinib Ditosylate; Placebo |
2011 | Diagnostic Study of Early Breast Cancer Using Ultrasound | https://clinicaltrials.gov/study/NCT01391039 | Terminated | Toronto, Ontario, Canada | Perflutren lipid microsphere |
2013 | The Prone Breast Radiation Therapy Trial | https://clinicaltrials.gov/study/NCT01815476 | Completed | Canada, various locations | Radiation Therapy Positioning Intervention |
2007 | Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast | https://clinicaltrials.gov/study/NCT00556907 | Terminated | Los Angeles, California | Radiation; Intraoperative radiotherapy |
2008 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | https://clinicaltrials.gov/study/NCT00769379 | Active Not Recruiting | Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; District of Columbia; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington; West Virginia; Wisconsin; Wyoming; various locations; Canada, various location; Seoul, Korea; San Juan, Puerto Rico | Biomarker; Trastuzumab; Radiation; Whole Breast Irradiation |
2011 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | https://clinicaltrials.gov/study/NCT01372618 | Terminated | New York, New York | SOM 230 / Pasireotide |
2023 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | https://clinicaltrials.gov/study/NCT05900986 | Recruiting | Scottsdale, Arizona; Washington, District of Columbia; Weston, Florida; Bronx, New York, Winston-Salem, North Carolina; Cleveland, Ohio; Philadelphia, Pennsylvania; Dallas, Houston, Texas | LS301-IT |
2019 | Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma | https://clinicaltrials.gov/study/NCT03909282 | Recruiting | Stanford, California | Lumpectomy; Radiation; Partial breast irradiation |
2016 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant | https://clinicaltrials.gov/study/NCT02540330 | Terminated | Baltimore, Maryland; Bronx, New York, New York | Fulvestrant |
2018 | MRI Characterization of Mammographically Detected DCIS | https://clinicaltrials.gov/study/NCT03495011 | Active Not Recruiting | Seattle, Washington | MRI; Biomarker |
2009 | Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS) | https://clinicaltrials.gov/study/NCT00890994 | Completed | Rochester, Minnesota | |
2015 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI) | https://clinicaltrials.gov/study/NCT02365714 | Terminated | Washington, District of Columbia | Radiation; CK Stereotactic Accelerated Partial Breast Irradiation |
2008 | Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery | https://clinicaltrials.gov/study/NCT00671476 | Unknown | Eureka, Santa Monica, California | pegylated liposomal doxorubicin hydrochloride; DNA methylation; TdT-mediated dUTP nick end labeling assay; fluorescence in situ hybridization; loss of heterozygosity; polymerase chain reaction; immunoenzyme; immunohistochemistry staining; biomarker; breast duct lavage |
2010 | Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer | https://clinicaltrials.gov/study/NCT01112254 | Completed | Villejuif, France | Magnetic Resonance Imaging; MRI, biopsy |
2009 | Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast | https://clinicaltrials.gov/study/NCT00788112 | Completed | San Francisco, California | vorinostat; protein expression; immunohistochemistry staining; biomarker |
2024 | Role of MRI Breast in Detection of Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT06744140 | Active Not Recruiting | Lahore, Punjab, Pakistan | Magnetic Resonance Imaging; MRI |
2018 | Ruxolitinib for Premalignant Breast Disease | https://clinicaltrials.gov/study/NCT02928978 | Active Not Recruiting | Birmingham, Alabama; Indianapolis, Indiana; Bronx, New York, Chapel Hill, North Carolina; Nashville, Tennessee; Houston, Texas | Ruxolitinib; Placebo |
2012 | Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT01439711 | Completed | Various locations in California, Colorado, Delaware, Iowa, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Missouri, North Carolina, Ohio, Oklahoma, South Carolina, Texas, Virginia | letrozole; MRI |
2023 | Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment | https://clinicaltrials.gov/study/NCT05946759 | Completed | Paderborn, Germany | Histolog Scanner |
2023 | Excisional Vacuum-Assisted Breast Biopsy | https://clinicaltrials.gov/study/NCT05932758 | Recruiting | Milan, Italy | Excisional biopsy |
2022 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | https://clinicaltrials.gov/study/NCT04349111 | Withdrawn | Intra-operative Radiation Therapy - IORT | |
2005 | Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast | https://clinicaltrials.gov/study/NCT00107211 | Completed | Philadelphia, Pennsylvania | therapeutic autologous dendritic cells |
2024 | A Patient Navigation Program for Addressing Disparities in Breast Cancer Care | https://clinicaltrials.gov/study/NCT06350500 | Recruiting | Buffalo, New York | Patient Navigation; Questionnaire |
2014 | Effects of Diet and Exercise on Ductal Carcinoma in Situ | https://clinicaltrials.gov/study/NCT02224807 | Completed | Birmingham, Alabama | Progressive Resistance Training (PRT); healthy diet; weight loss |
2003 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ | https://clinicaltrials.gov/study/NCT00072462 | Completed | Various locations in Australia, Austria, Belgium, Chile, France, Germany, Hungary, Ireland, Italy, Malta, Sweden, Switzerland, Turkey, United Kingdom | Tamoxifen citrate; Anastrozole |
2021 | Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ | https://clinicaltrials.gov/study/NCT04666961 | Recruiting | France, various locations | Tamoxifen; Anastrozole |
2012 | Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® | https://clinicaltrials.gov/study/NCT01644669 | Active Not Recruiting | Various locations in Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, New Hampshire, New York, Oklahoma, Tennessee, Virginia; Australia; Portugal | Intra-operative Radiation Therapy - IORT |
2009 | Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy | https://clinicaltrials.gov/study/NCT00843167 | Completed | Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, 97239-3098, United States | Diet; Broccoli sprout extract; Placebo |
2020 | Molecular Analysis of the Sloane Project | https://clinicaltrials.gov/study/NCT05868252 | Enrolling By Invitation | London, United Kingdom | |
2004 | Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer | https://clinicaltrials.gov/study/NCT00896857 | Completed | RNA; polymerase chain reaction; protein expression; reverse transcriptase-polymerase chain reaction; western blotting; immunoenzyme; immunohistochemistry staining; biomarker; breast duct lavage | |
2003 | Educational Interventions for Patients With DCIS | https://clinicaltrials.gov/study/NCT00148655 | Completed | Boston, Massachusetts | Decision Board |
2007 | Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia | https://clinicaltrials.gov/study/NCT00627276 | Completed | Portland, Oregon | Diet; omega-3 fatty acid; placebo |
2018 | Abbreviated Breast MRI After Cancer Treatment | https://clinicaltrials.gov/study/NCT03664778 | Active Not Recruiting | Philadelphia, Pennsylvania |